Pharmafile Logo
Pharmafocus logo
Advanced Search
regeneron

Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal

October 14, 2016
Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD

Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …

News

NICE plans new “fast-track” appraisal option

October 14, 2016
Medical Communications, Sales and Marketing NHS, NICE

The National Institute for Health and Care Excellence (NICE) has proposed the introduction of a fast-track process which could make …

News
janssen_latest_logo_on_sign

NICE knocks back Janssen rare disease drug

October 13, 2016
Medical Communications Janssen, NICE, imbruvica

NICE has announced its rejection of Janssen’s Imbruvica (ibrutinib) for the treatment of specific cases of Waldenstrom’s macroglobulinaemia (WM) – …

News
1024px-lyrica

Pfizer loses UK patent infringement case over $5.1bn drug

October 13, 2016
Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, patent infringement, pregabalin

Pfizer has been dealt a significant blow as the UK Court of Appeal has rejected the company’s patent infringement claims …

News
joanna_horobin

Nordic Nanovector announces the appointment of Joanna Horobin as Non-Executive Board Director

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nordic Nanovector, appointment, norway

Nordic Nanovector announced on 12 October that Joanna Horobin was elected to its Board as non-executive director at the company’s …

Appointment

Merck KgaA foresees meeting 2018 objectives and plans for 2022

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, 2022, Germany, Merck KGaA

Speaking at its 2016 Capital Market Day about the progress it had made towards its 2018 objectives, CEO Stefan Oschmann …

News
finance

Sanofi lowers Q3 sales figures from 2015

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results

Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of …

News

New treatment for leukaemia nullifies cancer cells

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boston, Cancer, Germany, Harvard, Mainz University, leukaemia

New research was able to demonstrate that a targeted drug-based inactivation of two chromatin regulators would interrupt the self-renewal of …

News
sunpharma

Sun Pharmaceuticals hit with recall of over 31 thousand bottles of anti-depressants

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, India, US, america, sun pharmaceutical

Sun Pharmaceuticals have been forced to recall 31,762 bottles of anti-depressants from the US market after the FDA issued a …

News

Novartis’ Zykadia more effective than chemo, new study shows

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia

Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …

News
paul_navarre

Nestlé appoints Paul Navarre as CEO of Nestlé Skin Health

October 12, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Nestle skin health, Paul Navarre, nestle

The announcement of Paul Navarre’s appointed as CEO of Nestlé Skin Health was announced on 11 October. He will take …

Appointment
clinical_trial-web

Tesaro’s ovarian cancer drug success threatens market rivals

October 12, 2016
Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib

Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …

News

Gamida Cell receives Breakthrough Therapy Designation from FDA

October 12, 2016
Research and Development Breakthrough Therapy Designation, FDA, Gamida Cell, leukaemia, lymphoma

Gamida Cell have been granted a Breakthrough Therapy Designation for their NiCord drug. NiCord has already passed through Phase I …

News
transgene

Transgene announce key partnership with Merck KGaA and Pfizer

October 12, 2016
Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck

Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …

News

NICE backs Celgene’s Otezla for psoriatic arthritis

October 12, 2016
Research and Development, Sales and Marketing Celgene, NICE, otezla

The national Institute of Health and Care Excellence has issued recommendation of Celgene’s Otezla (apremilast) for the treatment of psoriatic …

News
astrazeneca_logo_building

AstraZeneca forced to abandon Phase II trial

October 12, 2016
Research and Development AstraZeneca, Synairgen, asthma, cold, common cold

Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …

News
aaeaaqaaaaaaaaiyaaaajgqxy2rmmzrlltrhmzktndzhns05mza3lwmwmjliywjmzdu5zg

Sanofi appoint Alan Main to Executive Committee and Executive Vice President Consumer Healthcare

October 11, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Sanofi announced the appointment of Alan Main as Executive Vice President Consumer Healthcare effective October 1.Mr Main, who previously worked …

Appointment
exelixis_hq_web

Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016
Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …

News
nordicnanovector_final_logo

Nordic Nanovector and LegoChem Biosciences enter into collaboration

October 11, 2016
Manufacturing and Production

The Norwegian company Nordic Nanovector and the South Korean company LegoChem Biosciences have begun a collaboration to develop novel CD37-targeting …

News
takeda_world

Takeda enters $790m cancer development deal

October 11, 2016
Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody

Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …

News
The Gateway to Local Adoption Series

Latest content

Study explores genomic testing approach for unexplained infertility

May 14, 2026

Celtic Renewables receives £7m to develop bio-based solvents

May 14, 2026

Synnovis and SOPHiA GENETICS expand liquid biopsy testing in NHS cancer care

May 13, 2026

MHRA to establish Northern Ireland hub for life sciences sector

May 13, 2026

Shilpa Medicare signs manufacturing deal with NXI Therapeutics

May 12, 2026